Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...

Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis. The ...

University of Copenhagen researchers have developed a prototype patch for treating plaque psoriasis, which may simplify ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily ...

Reviewed by Lexie CornerNov 13 2024 According to a study published in Biomaterials Advances, scientists at the University of ...

Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis. The ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

Researchers conducted a nationwide cohort study using data from the Taiwan National Health Insurance database and the Taiwan ...

Vista, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced a strategic partnership with the National Psoriasis ...

Low patient satisfaction in psoriasis and psoriatic arthritis for clinicians and treatment is tied to need for better ...

Jefferies analyst Michael Yee has maintained their bullish stance on ORKA stock, giving a Buy rating today.Don't Miss our Black Friday ...